In line with our results, an independent report suggested NF1 alterations were potentially involved in ALK resistance [53] and a case report described a de novo NRASQ61K mutation upon development of ALK inhibitor resistance in a lorlatinib-treated neuroblastoma [54]. The gene discussed is ALK; the disease is neuroblastoma.